

ILUMYA ENROLLMENT FORM

PATIENT INFORMATION

Last Name _____ First Name _____
 Social Security No _____ Date of Birth _____
 Sex M F Weight _____ Height _____
 Home Phone _____ Work/Mobile _____
 Home Address _____
 State _____ Zip _____

PATIENT INSURANCE INFORMATION

Primary Medical Insurance _____ Medical Insurance Phone _____
 Secondary Medical Insurance _____ Medical Insurance Phone _____
 Subscriber Name _____
 Rx Card (PBM) _____ Group No _____
 Prescription Card Bin #: _____ PCN #: _____

TREATMENT ARRANGEMENTS

Start Date: _____ Ship Meds Home Doctor's Office _____ Teaching by: Doctor's Office Other: _____

STATEMENT OF MEDICAL NECESSITY

L40.0 Psoriasis L40.52 Psoriatic Arthritis L41.4 Plaque Psoriasis L73.2 Hidradenitis Suppurative L20.9 Atopic dermatitis L40.8 Moderate to Severe Plaque Psoriasis
 Other: _____ Date of Diagnosis: _____ OR Years With Disease _____

Medication assessment (Within Last 12 Months)

Atopic dermatitis Moderate Moderate to Severe Severe
 Psoriasis Severity: Moderate Moderate to Severe Severe
 Psoriasis Type: Plaque Other: _____

Patient Evaluation:

- Has Patient been diagnosed with Heart Failure? Yes No
- Has Patient been diagnosed with Lymphoma? Yes No
- Does Patient have serious/active infection? Yes No
- Has TB test been performed?
 If yes, results: _____ Comments: _____
- Has Hepatitis B been ruled out or treatment been initiated? Yes No
- Does Patient have latex allergy? Yes No
- Is Patient's platelet count >52,000 cells/uL? Yes No
- Patient Weight: _____ kg/lb
- Allergies: _____ NKDA

Prior (FAILED) Medications:

Medication	Reason for Discontinuation
Biologics: <input type="checkbox"/> Humira <input type="checkbox"/> Enbrel <input type="checkbox"/> Stelara	_____
<input type="checkbox"/> Others: _____	_____
<input type="checkbox"/> Methotrexate NA	_____
<input type="checkbox"/> Topicals: _____	_____

Patient Evaluation Cont.



NOTES: _____

PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> ILUMYA® (tildrakizumab-asmn)	<input type="checkbox"/> 100mg/ml Prefilled syringe <input type="checkbox"/>	<input type="checkbox"/> Inject 100mg subcutaneously at week 0, week 4 and every 12 weeks thereafter. <input type="checkbox"/> Others	<input type="checkbox"/> 1-month supply <input type="checkbox"/> 3-month supply <input type="checkbox"/>

Physician Signature: x _____ DAW (Dispense as Written) Date: _____

Physician Name: _____ Phone: _____ Fax: _____ Office Contact: _____

Physician Address: _____ NPI: _____ DEA: _____

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake. Then destroy this document. Please direct all verification or notification to the above mentioned physician's office.

By Signing this prescription and using Southside pharmacy's services you authorize Southside Pharmacy to contact Insurance companies for prior authorization purposes on your behalf.

FAX TO (855)-822-7838

Specialty Pharmacy | IV Therapy | Home Health | Medical Equipment | Physician's Billing

7700 Main St., Houston, TX 77030 | P: 855-822-7828 | www.ssr.com

"One SOURCE for ALL your Medical NEEDS"



Specialty Pharmacy | Infusion Services